AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie adjusted After-Tax Earnings — Non-GAAP ($M) ($M)
Form 8-K Non-GAAP Reconciliations
Latest, Q2 2026
6,491
Period ended Jun 30, 2026
Change on a year earlier
+23.0%
5,278 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
16
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up adjusted after-tax earnings — non-gaap ($m)
- Reported After-Tax Earnings — GAAP ($M)3,613 · Q2 2026
- Adjusted Pre-Tax Earnings — Non-GAAP ($M)7,613 · Q2 2026
- Reported Pre-Tax Earnings — GAAP ($M)4,278 · Q2 2026
- Adjusted Cost of Products Sold — Non-GAAP ($M)2,598 · Q2 2026
- Adjusted SG&A Expense — Non-GAAP ($M)3,574 · Q2 2026
- Adjusted Income Tax Expense — Non-GAAP ($M)1,119 · Q2 2026
Cite this data
StockData. (2026). AbbVie Adjusted After-Tax Earnings — Non-GAAP ($M) ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap_adj_aftertax
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.